17/08/2020
EQS-News

Zur Rose Group successfully concluded acquisition of the e-commerce and diabetes activities of Apotal Group

EQS Group-News: Zur Rose Group AG / Key word(s): Takeover
17.08.2020 / 17:46

Press release

Zur Rose Group successfully concluded acquisition of the e-commerce and diabetes activities of Apotal Group

The Zur Rose Group has successfully completed the acquisition of the e-commerce and diabetes activities of Apotal. In the course of this transaction, the Group acquired adbest GmbH, Hilter, Ultrapharm Medicalprodukte GmbH, Bad Rothenfelde, and Dia Plus Minus Handelsgesellschaft mbH, Hilter. For payment of the share portion of the purchase price, Zur Rose Group AG has increased the share capital recorded in the commercial register from 10,380,795 shares by 133,174 shares to 10,513,969 shares with a par value of CHF 30.00 each. The new shares have been issued out of the existing authorised capital.
 

Investors and analyst contact
Christoph Herrmann, Head of Investor Relations
Email: ir@zurrose.com, phone: +41 58 810 11 49

Media contact
Lisa Lüthi, Head of Group Communications
Email: media@zurrose.com, phone: +41 52 724 08 14

Agenda
19 August 2020 Half-Year Results
21 October 2020 Q3 Trading Update

Zur Rose Group

The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. It also operates the leading marketplace in southern Europe for consumer health, beauty and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany's best-known pharmacy brand DocMorris. Zur Rose employs more than 1,800 people at sites in Switzerland, Germany, the Netherlands, Spain and France. In 2019 it generated revenue of CHF 1,569 million (including medpex) and currently has around nine million active customers in core European markets.

With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care. It is also characterized by the continuous further development of digital services in the field of drug management using AI-supported applications and new technology. Zur Rose is furthermore actively driving ahead its positioning as a comprehensive provider of healthcare services. By creating a digital healthcare platform - the Zur Rose ecosystem - it networks products and digital services from qualified providers. The contribution made by Zur Rose will be to take these offerings to customers and patients and to make a relevant selection. The aim is to provide people with a seamless accompaniment and empower them to manage their own health optimally using products and digital solutions.

The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information please see zurrosegroup.com.



End of Corporate News



show this
Media Release (PDF)
Zur Rose Group
06/04/2022
Ad hoc News

Zur Rose Group AG publishes invitation to the Annual General Meeting of 28 April 2022

Read more
Max Müller to
28/03/2022
Corporate News

Max Müller to be new CEO of TeleClinic, taking over from founder and former CEO Katharina Jünger

Read more
Zur Rose Group:
24/03/2022
Ad hoc News

Zur Rose Group: Excellent starting position for e-prescriptions set up and ecosystem strategy successfully continued

Read more
Zur Rose Group:
20/01/2022
Corporate News

Zur Rose Group: steady growth in a volatile market environment

Read more
Zur Rose Group
10/01/2022
Corporate News

Zur Rose Group nominates Rongrong Hu as director

Read more
Zur Rose and
16/12/2021
Corporate News

Zur Rose and the Swiss Association for the Blind and Visually Impaired make it easier for people with a visual impairment to take medication

Read more
01/06